SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-007784
Filing Date
2024-02-26
Accepted
2024-02-26 10:48:13
Documents
21
Period of Report
2024-02-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45405
2 ex10-1.htm EX-10.1 440988
3 ex99-1.htm EX-99.1 14773
4 ex10-1_001.jpg GRAPHIC 23706
5 ex10-1_002.jpg GRAPHIC 34323
6 ex10-1_003.jpg GRAPHIC 6160
7 ex99-1_001.jpg GRAPHIC 9257
  Complete submission text file 0001493152-24-007784.txt   873788

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE lixt-20240223.xsd EX-101.SCH 3519
9 XBRL DEFINITION FILE lixt-20240223_def.xml EX-101.DEF 26564
10 XBRL LABEL FILE lixt-20240223_lab.xml EX-101.LAB 36548
11 XBRL PRESENTATION FILE lixt-20240223_pre.xml EX-101.PRE 25188
23 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5209
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 24674706
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)